AFP and hepatocellular carcinoma: In addition, immunofluorescence staining demonstrated that DC101 not only reduced both mouse VEGFR2-positive ECs and human AFP-positive HCC cells (Figure 1I–K) but also disrupted the proximity of human AFP-positive HCC cells to mouse VEGFR2-positive ECs (Figure 1L).